NTLA

Intellia Therapeutics, Inc. (NTLA) ESG Analysis Analysis (2026)

Invetso Score: 7.3/10 — Strong · Last Updated: 2026-08-01

Environmental

NTLA’s gene-editing platform likely carries lower direct environmental intensity than large-scale manufacturing peers, because its R&D-heavy model reduces energy, water, and waste exposure.

The company’s high R&D-to-revenue ratio suggests a research-centric footprint, which is generally less resource-intensive than peers with broader clinical manufacturing operations.

Limited leverage reduces the risk of capital constraints forcing environmentally inefficient operating decisions, compared with more indebted biotech peers.

No disclosed environmental controversies in the provided data supports a cleaner relative profile, although peer comparisons remain constrained by limited public metrics.

Social

NTLA’s social profile is supported by a science-driven business model, because patient benefit and clinical integrity are central to its long-term stakeholder license to operate.

High R&D intensity indicates sustained investment in therapeutic development, which can strengthen patient-oriented social impact relative to peers with thinner innovation pipelines.

Stock-based compensation remains material, but it is not unusually high for a development-stage biotech, so dilution-related employee alignment concerns appear manageable versus peers.

No evidence of major labor, product-safety, or community controversies in the provided data suggests a relatively stable social risk profile.

Governance

NTLA’s low debt burden supports governance flexibility, because limited creditor pressure reduces the likelihood of risk-taking driven by balance-sheet stress.

Stock-based compensation at a meaningful level can weaken capital discipline if persistent, since equity issuance may dilute shareholders more than at better-aligned peers.

Negative gross margin reflects an early-stage operating model, which increases governance scrutiny around resource allocation and milestone execution versus more mature peers.

The absence of provided controversy data limits downside evidence, but the available metrics do not indicate a clearly superior governance position relative to top-tier peers.

Overall Score

NTLA screens as a strong ESG relative to peers, led by a research-intensive operating model and low leverage, while governance remains only moderate due to capital-discipline concerns.

Score Driver: Research-Intensive Model With Low Leverage And Limited Direct Environmental Burden

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Intellia Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →